Literature DB >> 21093169

Radiation enhances regulatory T cell representation.

Evelyn L Kachikwu1, Keisuke S Iwamoto, Yu-Pei Liao, John J DeMarco, Nzhde Agazaryan, James S Economou, William H McBride, Dörthe Schaue.   

Abstract

PURPOSE: Immunotherapy could be a useful adjunct to standard cytotoxic therapies such as radiation in patients with micrometastatic disease, although successful integration of immunotherapy into treatment protocols will require further understanding of how standard therapies affect the generation of antitumor immune responses. This study was undertaken to evaluate the impact of radiation therapy (RT) on immunosuppressive T regulatory (Treg) cells. METHODS AND MATERIALS: Treg cells were identified as a CD4(+)CD25(hi)Foxp3(+) lymphocyte subset, and their fate was followed in a murine TRAMP C1 model of prostate cancer in mice with and without RT.
RESULTS: CD4(+)CD25(hi)Foxp3(+) Treg cells increased in immune organs after local leg or whole-body radiation. A large part, but not all, of this increase after leg-only irradiation could be ascribed to radiation scatter and Treg cells being intrinsically more radiation resistant than other lymphocyte subpopulations, resulting in their selection. Their functional activity on a per-cell basis was not affected by radiation exposure. Similar findings were made with mice receiving local RT to murine prostate tumors growing in the leg. The importance of the Treg cell population in the response to RT was shown by systemic elimination of Treg cells, which greatly enhanced radiation-induced tumor regression.
CONCLUSIONS: We conclude that Treg cells are more resistant to radiation than other lymphocytes, resulting in their preferential increase. Treg cells may form an important homeostatic mechanism for tissues injured by radiation, and in a tumor context, they may assist in immune evasion during therapy. Targeting this population may allow enhancement of radiotherapeutic benefit through immune modulation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21093169      PMCID: PMC3117954          DOI: 10.1016/j.ijrobp.2010.09.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

Review 1.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

Review 2.  IL-2, regulatory T cells, and tolerance.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

3.  Abdominal radiation exposure elicits inflammatory responses and abscopal effects in the lungs of mice.

Authors:  A Van der Meeren; P Monti; M Vandamme; C Squiban; J Wysocki; N Griffiths
Journal:  Radiat Res       Date:  2005-02       Impact factor: 2.841

4.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.

Authors:  Akio Ohta; Akiko Ohta; Manasa Madasu; Radhika Kini; Meenakshi Subramanian; Nipun Goel; Michail Sitkovsky
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

Review 7.  Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.

Authors:  M Sitkovsky; D Lukashev; S Deaglio; K Dwyer; S C Robson; A Ohta
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  136 in total

Review 1.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

Review 2.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

3.  ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Authors:  Frank P Vendetti; Pooja Karukonda; David A Clump; Troy Teo; Ronald Lalonde; Katriana Nugent; Matthew Ballew; Brian F Kiesel; Jan H Beumer; Saumendra N Sarkar; Thomas P Conrads; Mark J O'Connor; Robert L Ferris; Phuoc T Tran; Greg M Delgoffe; Christopher J Bakkenist
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

4.  The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Authors:  Michael Spiotto; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Sci Immunol       Date:  2016-09-30

Review 5.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

Review 6.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

7.  Developmental regulation of p53-dependent radiation-induced thymocyte apoptosis in mice.

Authors:  A Gentil Dit Maurin; C Lemercier; V Collin-Faure; P N Marche; E Jouvin-Marche; S M Candéias
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

8.  Tumour radiosensitivity is associated with immune activation in solid tumours.

Authors:  Tobin Strom; Louis B Harrison; Anna R Giuliano; Michael J Schell; Steven A Eschrich; Anders Berglund; William Fulp; Ram Thapa; Domenico Coppola; Sungjune Kim; Jessica Frakes; John Foekens; James J Mulé; Javier F Torres-Roca
Journal:  Eur J Cancer       Date:  2017-08-29       Impact factor: 9.162

9.  Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

10.  Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Authors:  Brian M Olson; Ewa Jankowska-Gan; Jordan T Becker; Dario A A Vignali; William J Burlingham; Douglas G McNeel
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.